Certara (NASDAQ:CERT – Get Free Report) issued an update on its FY24 earnings guidance on Tuesday morning. The company provided earnings per share (EPS) guidance of $0.41 to $0.46 for the period, compared to the consensus estimate of $0.44. The company issued revenue guidance of $385 million to $400 million, compared to the consensus revenue estimate of $391.38 million.
Certara Stock Performance
CERT stock traded up $0.04 during midday trading on Thursday, hitting $13.07. The stock had a trading volume of 723,355 shares, compared to its average volume of 574,003. The firm has a market capitalization of $2.10 billion, a price-to-earnings ratio of -34.85, a P/E/G ratio of 5.39 and a beta of 1.52. Certara has a 52 week low of $11.81 and a 52 week high of $19.87. The stock has a 50-day simple moving average of $15.10 and a 200 day simple moving average of $16.52. The company has a current ratio of 3.26, a quick ratio of 3.26 and a debt-to-equity ratio of 0.27.
Certara (NASDAQ:CERT – Get Free Report) last issued its earnings results on Tuesday, August 6th. The company reported $0.07 EPS for the quarter, missing the consensus estimate of $0.10 by ($0.03). The firm had revenue of $93.31 million during the quarter, compared to the consensus estimate of $96.01 million. Certara had a positive return on equity of 4.08% and a negative net margin of 17.02%. The firm’s revenue for the quarter was up 3.2% compared to the same quarter last year. During the same period last year, the business earned $0.10 earnings per share. As a group, equities research analysts anticipate that Certara will post 0.28 earnings per share for the current year.
Wall Street Analyst Weigh In
Read Our Latest Research Report on Certara
About Certara
Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.
Recommended Stories
- Five stocks we like better than Certara
- What Are Dividend Achievers? An Introduction
- Owens-Corning Stock: Good Value or Recession Red Flag?
- Profitably Trade Stocks at 52-Week Highs
- Datadog Exceeds Q2 Expectations, Solidifies Market Leadership
- What Are Growth Stocks and Investing in Them
- Cybersecurity Stock Surges, Promising Double-Digit Gains
Receive News & Ratings for Certara Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Certara and related companies with MarketBeat.com's FREE daily email newsletter.